Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 10:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1729–1752 of 22,226 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: control 2 Clear all

Conditions: Hidradenitis Suppurativa
Interventions: Tulisokibart, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 19
States / cities: Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 16 more

Conditions: ACL Surgery, Pain Management
Interventions: Meloxicam 15 mg, Medrol 4 MG Oral Tablet Includes Medrol Dosepak, Gabapentin 300 mg, Hydrocodone 5Mg/Acetaminophen 325Mg Tab, Ketorolac 10 Mg Oral Tablet; Drug
Lead sponsor: St. Louis University; Other
Eligibility: 13 Years to 50 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Abuse Potential
Interventions: Placebo, Alprazolam 2 mg, Gabapentin Enacarbil Immediate Release (GE-IR) 200 mg, Gabapentin Enacarbil Immediate Release (GE-IR) 450 mg, Gabapentin Enacarbil Immediate Release (GE-IR) 700 mg; Drug
Lead sponsor: Arbor Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Interventions: CB-839, Cabozantinib, Placebo; Drug
Lead sponsor: Calithera Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 444 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 59
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more

Conditions: Mesothelioma
Interventions: Anetumab ravtansine (BAY94-9343), Vinorelbine; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 15
States / cities: La Jolla, California • Aurora, Colorado • Norwich, Connecticut + 11 more

Conditions: Major Depressive Disorder
Interventions: Brexpiprazole, Antidepressant therapy; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Depression, Racism
Interventions: Short videos; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 14 Years to 18 Years
Enrollment: 1,291 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Contraception
Interventions: Misoprostol, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Influenza
Interventions: VXA-A1.1 Oral Vaccine, VXA Placebo Tablet; Biological
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Cypress, California

Conditions: SARS-CoV-2 Infection
Interventions: Convalescent Plasma (anti-SARS-CoV-2 plasma), Non-convalescent Plasma (control plasma); Biological
Lead sponsor: Max O'Donnell; Other
Eligibility: 18 Years and older
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Schizophrenia
Interventions: LB-102; Drug
Lead sponsor: LB Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Chronic Idiopathic Urticaria, Chronic Idiopathic Pruritus, Lichen Planus, Lichen Simplex Chronicus, Plaque Psoriasis
Interventions: KPL-716, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 14
States / cities: Anniston, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 11 more

Conditions: Pregnancy Related, Gestational Weight Gain, Postpartum Weight Retention, Overweight and Obesity
Interventions: GROWell (Interactive Obesity Treatment Approach), Attention Support Control; Behavioral
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 480 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Davis, California

Conditions: Dizziness, Vertigo
Interventions: Pentoxifylline, Placebo; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 40 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Mental Health, Suicide
Interventions: Messaging, Wait list control; Behavioral · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 89 Years
Enrollment: 355 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Canandaigua, New York

Conditions: Hernia, Inguinal
Interventions: ULTRAPRO Mesh, 3DMAX, Evaluation; Device · Other
Lead sponsor: South East Area Health Education Center, Wilmington, NC; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Hand Injuries and Disorders, Anesthesia, Local, Upper Extremity Injury
Interventions: standard intravenous regional anesthesia (IVRA) with reapplication of esmach; Procedure
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 100 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Healthy Volunteers, Pharmacokinetics of ASP1941
Interventions: ASP1941, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Colorectal Cancer Screening
Interventions: Not listed
Lead sponsor: IntelliGeneScan, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Meniscus Disorder, Narcotic Use
Interventions: Celecoxib, Hydrocodon/Acetaminophen, Ketorolac, Gabapentin, Acetaminophen, Diazepam; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Homozygous Familial Hypercholesterolemia
Interventions: Alirocumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 4
States / cities: Boca Raton, Florida • New York, New York • Cincinnati, Ohio + 1 more

Conditions: Methamphetamine Abuse
Interventions: normal saline, ch-mAb7f9; Biological
Lead sponsor: InterveXion Therapeutics, LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Diabetes Mellitus, Type 2
Interventions: Self-Affirmation; Behavioral
Lead sponsor: Elizabeth Scharnetzki; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Westbrook, Maine

Conditions: Transplant; Failure, Kidney, Renal Disease, End Stage, Hyperparathyroidism, Secondary
Interventions: Paricalcitol, Corticosteroid Avoidance Immune Suppression Protocol; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 2
States / cities: Scottsdale, Arizona • Rochester, Minnesota

Search by objective public record fields.

Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)

Efficacy of Methylprednisolone for Pain Control After ACL Repair

An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users

CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma

Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)

A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder

Reducing Depression-related Stigma and Increasing-treatment Seeking Among Black Adolescents

Misoprostol Prior to Intrauterine Device (IUD) Insertion in Nulliparous Women

Safety Study of an Oral Vaccine to Prevent Seasonal Influenza

Plasma Therapy of COVID-19 in Severely Ill Patients

Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults

A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases

Goals for Reaching Optimal Wellness: GROWell

Trental for the Treatment of Vertigo/Dizziness/Imbalance

Public Messaging to Increase Treatment Seeking for Veterans at Risk for Suicide

Prospective Trial Comparing Two Different Polypropylene Meshes for Inguinal Hernias

Evaluation of Second Esmarch Application on Intravenous Regional Anesthesia Effectiveness

Study of the Pharmacokinetics of ASP1941 and the Effect on Glucose Concentrations in Male and Female Young and Elderly Healthy Adults

Colorectal Cancer Screening Validation Study

Nonopioid Analgesia After Arthroscopic Meniscus Surgery

Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

Safety Study of Ch-mAb7F9 for Methamphetamine Abuse

Strategies to Improve Well-Being and Diabetes Management

Oral Paricalcitol in Kidney Transplant Recipients